Carisoprodol (Soma): a new and cautious perspective on an old agent - PubMed

Review

Carisoprodol (Soma): a new and cautious perspective on an old agent

R A Littrell et al. South Med J. 1993 Jul.

Abstract

Carisoprodol (Soma, others) is a commonly prescribed, noncontrolled, skeletal muscle relaxant whose active metabolite is meprobamate. Patients for whom carisoprodol is prescribed are at risk for meprobamate dependence; several such cases have been reported. Toxicity and withdrawal associated with the use of meprobamate is high and has led to abandonment of this agent in clinical practice. Because carisoprodol possesses the same risks it should be avoided when possible, and it should be given schedule IV controlled substance status.

Similar articles

• Carisoprodol: a drug of continuing abuse.

  Reeves RR, Pinkofsky HB, Carter OS. Reeves RR, et al. J Am Osteopath Assoc. 1997 Dec;97(12):723-4. doi: 10.7556/jaoa.1997.97.12.723. J Am Osteopath Assoc. 1997. PMID: 9439144

• Carisoprodol (soma): abuse potential and physician unawareness.

  Reeves RR, Carter OS, Pinkofsky HB, Struve FA, Bennett DM. Reeves RR, et al. J Addict Dis. 1999;18(2):51-6. doi: 10.1300/J069v18n02_05. J Addict Dis. 1999. PMID: 10334375

• Carisoprodol: update on abuse potential and legal status.

  Reeves RR, Burke RS, Kose S. Reeves RR, et al. South Med J. 2012 Nov;105(11):619-23. doi: 10.1097/SMJ.0b013e31826f5310. South Med J. 2012. PMID: 23128807 Review.

• Carisoprodol: abuse potential and withdrawal syndrome.

  Reeves RR, Burke RS. Reeves RR, et al. Curr Drug Abuse Rev. 2010 Mar;3(1):33-8. doi: 10.2174/1874473711003010033. Curr Drug Abuse Rev. 2010. PMID: 20088817 Review.

• Meprobamate dependence secondary to carisoprodol (Soma) use.

  Littrell RA, Sage T, Miller W. Littrell RA, et al. Am J Drug Alcohol Abuse. 1993;19(1):133-4. doi: 10.3109/00952999309002671. Am J Drug Alcohol Abuse. 1993. PMID: 8438828 No abstract available.

Cited by

• Carisoprodol-mediated modulation of GABAA receptors: in vitro and in vivo studies.

  Gonzalez LA, Gatch MB, Taylor CM, Bell-Horner CL, Forster MJ, Dillon GH. Gonzalez LA, et al. J Pharmacol Exp Ther. 2009 May;329(2):827-37. doi: 10.1124/jpet.109.151142. Epub 2009 Feb 24. J Pharmacol Exp Ther. 2009. PMID: 19244096 Free PMC article.

• Assessment of subunit-dependent direct gating and allosteric modulatory effects of carisoprodol at GABA(A) receptors.

  Kumar M, González LA, Dillon GH. Kumar M, et al. Neuropharmacology. 2015 Oct;97:414-25. doi: 10.1016/j.neuropharm.2015.04.007. Epub 2015 Apr 18. Neuropharmacology. 2015. PMID: 25896767 Free PMC article.

• Carisoprodol Single and Multiple Dose PK-PD. Part II: Pharmacodynamics Evaluation Method for Central Muscle Relaxants. Double-Blind Placebo-Controlled Clinical Trial in Healthy Volunteers.

  Calvo A, González-Hidalgo M, Terleira A, Fernández N, Portolés A. Calvo A, et al. J Clin Med. 2022 Feb 21;11(4):1141. doi: 10.3390/jcm11041141. J Clin Med. 2022. PMID: 35207414 Free PMC article.

• Abuse Potential of Soma: the GABA(A) Receptor as a Target.

  Gonzalez LA, Gatch MB, Forster MJ, Dillon GH. Gonzalez LA, et al. Mol Cell Pharmacol. 2009 Jan 1;1(4):180-186. Mol Cell Pharmacol. 2009. PMID: 20419052 Free PMC article.

• Muscle relaxants for non-specific low back pain.

  van Tulder MW, Touray T, Furlan AD, Solway S, Bouter LM. van Tulder MW, et al. Cochrane Database Syst Rev. 2003;2003(2):CD004252. doi: 10.1002/14651858.CD004252. Cochrane Database Syst Rev. 2003. PMID: 12804507 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.

• Medical

  • MedlinePlus Consumer Health Information
  • MedlinePlus Health Information